Additionally, compounds targeting receptors indirectly involved in the ECS, such as Trpv-1 and GPR-55, exhibited neuroprotective and anti-inflammatory properties, indicating broader intervention targets for AD treatment. This evidence concerns the gene TRPV1 and Alzheimer disease.